Bangladesh · Delayed Price · Currency is BDT DSE:SQURPHARMA Statistics
Total Valuation
DSE:SQURPHARMA has a market cap or net worth of BDT 192.36 billion. The enterprise value is 120.15 billion.
| Market Cap | 192.36B |
| Enterprise Value | 120.15B |
Important Dates
The next estimated earnings date is Thursday, October 22, 2026.
| Earnings Date | Oct 22, 2026 |
| Ex-Dividend Date | Nov 17, 2025 |
Share Statistics
DSE:SQURPHARMA has 886.45 million shares outstanding.
| Current Share Class | 886.45M |
| Shares Outstanding | 886.45M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.04% |
| Owned by Insiders (%) | 44.10% |
| Owned by Institutions (%) | 3.56% |
| Float | 495.49M |
Valuation Ratios
The trailing PE ratio is 7.44 and the forward PE ratio is 6.50.
| PE Ratio | 7.44 |
| Forward PE | 6.50 |
| PS Ratio | 2.30 |
| PB Ratio | 1.28 |
| P/TBV Ratio | 1.28 |
| P/FCF Ratio | 13.76 |
| P/OCF Ratio | 8.63 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.50, with an EV/FCF ratio of 8.60.
| EV / Earnings | 4.65 |
| EV / Sales | 1.44 |
| EV / EBITDA | 4.50 |
| EV / EBIT | 4.90 |
| EV / FCF | 8.60 |
Financial Position
The company has a current ratio of 13.78, with a Debt / Equity ratio of 0.00.
| Current Ratio | 13.78 |
| Quick Ratio | 11.26 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.01 |
| Debt / FCF | 0.03 |
| Interest Coverage | 185.75 |
Financial Efficiency
Return on equity (ROE) is 18.14% and return on invested capital (ROIC) is 20.48%.
| Return on Equity (ROE) | 18.14% |
| Return on Assets (ROA) | 9.10% |
| Return on Invested Capital (ROIC) | 20.48% |
| Return on Capital Employed (ROCE) | 14.36% |
| Weighted Average Cost of Capital (WACC) | 4.75% |
| Revenue Per Employee | 5.24M |
| Profits Per Employee | 1.62M |
| Employee Count | 15,937 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 3.19 |
Taxes
In the past 12 months, DSE:SQURPHARMA has paid 5.65 billion in taxes.
| Income Tax | 5.65B |
| Effective Tax Rate | 17.93% |
Stock Price Statistics
The stock price has increased by +6.43% in the last 52 weeks. The beta is 0.08, so DSE:SQURPHARMA's price volatility has been lower than the market average.
| Beta (5Y) | 0.08 |
| 52-Week Price Change | +6.43% |
| 50-Day Moving Average | 211.93 |
| 200-Day Moving Average | 213.34 |
| Relative Strength Index (RSI) | 64.96 |
| Average Volume (20 Days) | 353,000 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, DSE:SQURPHARMA had revenue of BDT 83.53 billion and earned 25.86 billion in profits. Earnings per share was 29.18.
| Revenue | 83.53B |
| Gross Profit | 40.29B |
| Operating Income | 21.82B |
| Pretax Income | 31.52B |
| Net Income | 25.86B |
| EBITDA | 24.03B |
| EBIT | 21.82B |
| Earnings Per Share (EPS) | 29.18 |
Balance Sheet
The company has 60.82 billion in cash and 356.03 million in debt, with a net cash position of 72.22 billion or 81.47 per share.
| Cash & Cash Equivalents | 60.82B |
| Total Debt | 356.03M |
| Net Cash | 72.22B |
| Net Cash Per Share | 81.47 |
| Equity (Book Value) | 150.51B |
| Book Value Per Share | 169.78 |
| Working Capital | 76.58B |
Cash Flow
In the last 12 months, operating cash flow was 22.30 billion and capital expenditures -8.32 billion, giving a free cash flow of 13.98 billion.
| Operating Cash Flow | 22.30B |
| Capital Expenditures | -8.32B |
| Depreciation & Amortization | 2.21B |
| Net Borrowing | -621.77M |
| Free Cash Flow | 13.98B |
| FCF Per Share | 15.77 |
Margins
Gross margin is 48.24%, with operating and profit margins of 26.12% and 30.96%.
| Gross Margin | 48.24% |
| Operating Margin | 26.12% |
| Pretax Margin | 37.73% |
| Profit Margin | 30.96% |
| EBITDA Margin | 28.77% |
| EBIT Margin | 26.12% |
| FCF Margin | 16.74% |
Dividends & Yields
This stock pays an annual dividend of 12.00, which amounts to a dividend yield of 5.53%.
| Dividend Per Share | 12.00 |
| Dividend Yield | 5.53% |
| Dividend Growth (YoY) | 9.09% |
| Years of Dividend Growth | 8 |
| Payout Ratio | 40.97% |
| Buyback Yield | n/a |
| Shareholder Yield | 5.51% |
| Earnings Yield | 13.44% |
| FCF Yield | 7.27% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for DSE:SQURPHARMA is 352.20, which is 62.38% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 352.20 |
| Price Target Difference | 62.38% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 11.24% |
| EPS Growth Forecast (3Y) | 12.28% |
Stock Splits
The last stock split was on November 23, 2020. It was a forward split with a ratio of 1.05.
| Last Split Date | Nov 23, 2020 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
DSE:SQURPHARMA has an Altman Z-Score of 18.17 and a Piotroski F-Score of 5.
| Altman Z-Score | 18.17 |
| Piotroski F-Score | 5 |